AMENDMENTS

IN THE CLAIMS:

Please amend claim 22 as set forth below.

Complete Listing of the Claims

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

1. (Previously presented) A F_V antibody construct having variable domains for CD16 and a CD30 but no constant domains and inducing a regression of Hodgkin's disease *in vivo*.

2. (Previously presented) The F_V antibody construct according to claim 1, wherein the CD16 is derived from natural killer cells (NK cells).

3. (Previously presented) The F_V antibody construct according to claim 1, wherein the CD30 is derived from a member selected from the group consisting of: Hodgkin's disease or Reed-Sternberg cells.

4. (Previously presented) The F_V antibody construct according to claim 1, wherein one binding site is present each.

5. (Previously presented) The F_V antibody construct according to claim 4, encoded by the expression vector pKID16-30 (DSM 12960).

6. (Previously presented) The F_V antibody construct according to claim 1, wherein two binding sites are present for each.

7. (Withdrawn) An expression vector, coding for the F_V antibody construct according to claim 1.

8. (Withdrawn) The expression vector according to claim 7, which is pKID16-30 (DSM 12960).

9. (Withdrawn) A transformant, containing the expression vector according to claim 7.

10. (Withdrawn) A method of producing the F_v antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.

11. (Withdrawn) A kit comprising:

(a) an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein

and/or

(b) an expression vector coding for said F_v antibody construct, and

(c) at least one auxiliary substance selected from the group consisting of buffers, solvents, carriers, controls and markers,

wherein one or more representatives of the individual components may be present.

12. (Withdrawn) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.

13. (Withdrawn) A method according to claim 12, wherein the cells are tumor cells.

14. (Withdrawn) A method according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

15. (Previously presented) The F_v antibody construct according to claim 2, wherein the CD30 is derived from a member selected from the group consisting of: Hodgkin's disease or Reed-Sternberg cells.

16. (Withdrawn) An expression vector, coding for the F_v antibody construct according to claim 15.

17. (Withdrawn) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein, wherein the CD16 receptor is derived from natural killer

cells (NK cells), and wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

18. (Withdrawn) A transformant, containing the expression vector according to claim 8.

19. (Previously presented) The F_V construct of claim 1, wherein said F_V antibody construct comprises elements (a) and (b) joined via a peptide linker:
(a) a VH domain of an anti-CD16 antibody and a VL domain of an anti-CD30 antibody, the domains being joined by a peptide linker; and
(b) a VH domain of an anti-CD30 antibody and a VL domain of an anti-CD16 antibody, the domains joined by a peptide linker.

20. (Withdrawn) A method of treatment of a tumor comprising the step of administering the F_V antibody construct according to claim 1.

21. (Withdrawn) The method of claim 20, wherein the treatment comprises the lysis of Hodgkin's disease or Reed-Sternberg cells.

22. (Currently amended) The F_V antibody construct according to claim 1, wherein said F_V antibody activates NK cells and produces greater lysis of CD30+ L540CY Hodgkin's disease cells ~~is capable of inducing a more intense lysis of CD30 carrying cells *in vitro*~~ than lysis of CD30+ L540CY Hodgkin's disease cells produced by bimAbHRS-3/A9 (DSM ACC2142), in a JAM cytotoxicity test.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK